Edwards Lifesciences Corp [EW] stock is trading at $62.01, up 2.16%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EW shares have lost -2.56% over the last week, with a monthly amount drifted -32.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on July 31, 2024, when Daiwa Securities upgraded its rating to a Outperform. Previously, Wolfe Research upgraded its rating to Peer Perform on July 29, 2024. On July 25, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $82 on the stock. TD Cowen downgraded its rating to a Hold and decreased its price target to $70 on July 25, 2024. Robert W. Baird downgraded its rating to a Neutral and reduced its price target to $70 on July 25, 2024. JP Morgan downgraded its rating to Neutral for this stock on July 25, 2024, and downed its price target to $72. In a note dated July 25, 2024, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $105 to $75.
Edwards Lifesciences Corp [EW] stock has fluctuated between $58.93 and $96.12 over the past year. Currently, Wall Street analysts expect the stock to reach $102.29 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $62.01 at the most recent close of the market. An investor can expect a potential return of 64.96% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 6.00B for the trailing twelve months, which represents a drop of -9.43%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.21 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.44 points at the first support level, and at 58.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.48, and for the 2nd resistance point, it is at 64.95.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 3.71. Further, the Quick Ratio stands at 2.87, while the Cash Ratio is 1.35. Considering the valuation of this stock, the price to sales ratio is 6.23, the price to book ratio is 5.02 and price to earnings (TTM) ratio is 25.52.
Transactions by insiders
Recent insider trading involved Lippis Daniel J., CVP, JAPAC, that happened on Jul 11 ’24 when 500.0 shares were sold. CVP,Strategy/Corp Development, BOBO DONALD E JR completed a deal on Jul 10 ’24 to sell 5000.0 shares. Meanwhile, CVP, Chief Financial Officer Ullem Scott B. sold 5625.0 shares on Jun 20 ’24.
